Skip to main content
Erschienen in: World Journal of Surgical Oncology 1/2018

Open Access 01.12.2018 | Review

Reconstruction options following pancreaticoduodenectomy after Roux-en-Y gastric bypass: a systematic review

verfasst von: William F. Morano, Mohammad F. Shaikh, Elizabeth M. Gleeson, Alvaro Galvez, Marian Khalili, John Lieb II, Elizabeth P. Renza-Stingone, Wilbur B. Bowne

Erschienen in: World Journal of Surgical Oncology | Ausgabe 1/2018

Abstract

Background

Obesity is a risk factor for pancreatic cancer which may be treated with Roux-en-Y gastric bypass and represents an increasing morbidity. Post-RYGB anatomy poses considerable challenges for reconstruction after pancreaticoduodenectomy (PD), a growing problem encountered by surgeons. We characterize specific strategies used for post-PD reconstruction in the RYGB patient.

Methods

PubMed search was performed using MeSH terms “Gastric Bypass” and “Pancreaticoduodenectomy” between 2000 and 2018. Articles reporting cases of pancreaticoduodenectomy in post-RYGB patients were included and systematically reviewed for this study.

Results

Three case reports and five case series (25 patients) addressed PD after RYGB; we report one additional case. The typical post-gastric bypass PD patient is a woman in the sixth decade of life, presenting most commonly with pain (69.2%) and/or jaundice (53.8%), median 5 years after RYGB. Five post-PD reconstructive options are reported. Among these, the gastric remnant was resected in 18 cases (69.2%), with reconstruction of biliopancreatic drainage most commonly achieved using the distal jejunal segment of the pre-existing biliopancreatic limb (73.1%). Similarly, in the eight cases where the gastric remnant was spared (30.8%), drainage was most commonly performed using the distal jejunal segment of the biliopancreatic limb (50%). Among the 17 cases reporting follow-up data, median was 27 months.

Conclusion

Reconstruction options after PD in the post-RYGB patient focus on resection or preservation gastric remnant, as well as creation of new biliopancreatic limb. Insufficient data exists to make recommendations regarding the optimal reconstruction option, yet surgeons must prepare for the possible clinical challenge. PD reconstruction post-RYGB requires evaluation through prospective studies.
Abkürzungen
CT
Computed tomography
DGE
Delayed gastric emptying
ERCP
Endoscope retrograde cholangiopancreatography
IQR
Inter-quartile range
MMC
Motor migratory complex
PD
Pancreaticoduodenectomy
RYGB
Roux-en-Y gastric bypass
TPN
Total parenteral nutrition

Background

Morbid obesity, a known risk factor for the development of pancreatic cancer, may be treated surgically with Roux-en-Y gastric bypass (RYGB). The post-bypass anatomy can make reconstruction after pancreaticoduodenectomy more complex, with multiple surgical options. Although uncommon, this situation will be encountered more frequently as the post-RYGB population increases in size. Few reported cases exist to provide evidence-based guidelines for options for reconstruction of the post-pancreaticoduodenectomy anatomy in a patient with prior Roux-en-Y gastric bypass.

Introduction

Obesity is a growing problem in the USA and known risk factor for development of pancreatic malignancy [13]. The Roux-en-Y gastric bypass (RYGB) has proven to be an effective, long-term solution for obesity and its associated morbidities [46]. RYGB addresses the problem of obesity in two ways: a restrictive component involving the creation of a gastric pouch with alimentary limb, and a malabsorptive component bypassing the proximal portion of the small intestine. The resultant configuration is a significant reconstruction and poses potential future diagnostic and therapeutic challenges [711]. In the case of pancreatic malignancy requiring pancreaticoduodenectomy (PD), the surgeon must consider whether or not to resect the gastric remnant, as well as the method of reconstruction of the biliopancreatic and alimentary limbs [12]. To date, few case reports or series of post-RYGB pancreaticoduodenectomies have directly addressed this challenging clinical scenario. With the growing prevalence of obese patients undergoing RYGB, surgeons will be facing similar issues more frequently in the future. We present such a case and systematically review the existing literature to report management strategies and discuss relevant considerations for reconstruction.

Methods

PubMed search was performed using MeSH terms “Gastric Bypass” and “Pancreaticoduodenectomy” between 2000 and 2018. We systematically reviewed and extracted data from included cases such as patient-related demographics, diagnosis, operative techniques, and outcomes. Articles in which no patient data was provided, operative technique-specific, and reports in which PD was not performed after RYGB were excluded from this review (Fig. 1). Qualitative variables are reported as proportions. Continuous quantitative variables are provided as medians with interquartile ranges.

Results

Our search returned 55 English language articles. Eight of these articles were found to specifically address PD after RYGB. In the included articles, 25 patient cases were reported; our institution included an additional case, for a total of 26 cases (Fig. 1) [1320]. Table 1 contains a synopsis of all reported cases with regard to clinicopathological characteristics. Tables 2 and 3 summarize patient pre-operative, operative, and post-operative characteristics, respectively. Briefly, the patients were predominantly female, in the sixth decade of life (median age 54 years, IQR 52–61). Median interval between gastric bypass and PD was 5 years (IQR 2–11). Patients initially presented with abdominal/back pain [18], jaundice [14], weight loss [9], nausea/vomiting [5], as an incidental finding [4], diarrhea [2], and fever/chills [1]. Computed tomography (CT) was the diagnostic modality of choice in all patients. Pathological diagnoses included pancreatic adenocarcinoma [15], neuroendocrine tumors [3], chronic pancreatitis [3], bile duct fibrosis [2], intraductal papillary mucinous neoplasm [1], duodenal adenocarcinoma [1], and ampullary adenocarcinoma [1]. Procedures included pancreaticoduodenectomy [21], pylorus-preserving pancreaticoduodenectomy [1], and total pancreatectomy [1]. Report of resection margin status [13] and histologic lymph node examination [4] for malignancies were infrequently provided. The gastric remnant was resected in majority of patients [18]. Few surgeons resected the entire biliopancreatic limb [3]. Reconstruction of biliopancreatic drainage was achieved by using distal jejunal segment of the old biliopancreatic limb [22], a new limb raised from the old common channel [3], a new limb raised from the old alimentary limb [1], and creation of a hepaticojejunostomy and pancreaticojejunostomy in-continuity with the old common channel and gastric pouch [1] (Fig. 2). In the reported cases, margin status was reported in 65% of patients with a diagnosis of malignancy. Three post-operative complications were reported: two pancreatic fistulas, one enterocutaneous fistula, and one bile leak from gastrojejunostomy anastomotic breakdown. Of the 17 cases reporting follow-up data (median 27 months), 10 patients had no evidence of disease at last follow-up, 8 died of malignancy.
Table 1
Overview of all relevant clinicopathological characteristics in the 26 cases reviewed of post-RYGB patients who underwent pancreaticoduodenectomy
Author
Year
Sex
Age
Diagnosis
Imaging/diagnostic modalities
Years from RYGB
RYGB type
Presenting complaint(s)
Resection specimen
Gastric remnant
Biliary drainage
Pancreatic drainage
Gastric remnant drainage
Feeding access
OR time (min)
EBL (cc)
N staging
Margins
Complications
Oncological Outcome
Follow-up (moths)
Helmick
2010
M
71
IPMN
CT
4
NR
Pain
SPDS
Spared
BL
BL
BL
GT
NR
NR
NR
NR
Bile leak
NED
NR
 
2010
F
58
CP
CT
5
NR
Pain, jaundice
SPDS
Spared
BL
BL
BL
GT
NR
NR
NR
N/A
NR
N/A
NR
Swain
2010
F
50
PDAC
CT
1.75
Open
Jaundice, weight loss
SPDS, GR
Resected
BL
BL
N/A
NR
NR
NR
NR
NR
NR
NED
12
  
F
55
NET
CT
2
Lap
Incidental finding
SPDS, GR
Resected
BL
BL
N/A
NR
NR
NR
NR
NR
Pancreatic leak
NED
12
  
F
61
PDAC
CT
25
Open loop
Incidental finding
SPDS, GR
Resected
BL
BL
N/A
NR
NR
NR
NR
NR
NR
NED
36
  
F
56
Ampullary Ca
CT
0.75
Lap
Fever/chills, jaundice
SPDS, GR, BL
Resected
AL
AL
N/A
NR
NR
NR
NR
NR
NR
NED
84
  
M
51
NET
CT, Perc
10
Open
Pain
PPPDS, BL
Spared
CC
CC
CC
NR
NR
NR
NR
NR
ECF
NED
NR
Cruz-Muñoz
2011
M
61
NET
CT
0.18
Lap
Incidental finding
SPDS, GR
Resected
BL
BL
N/A
NR
410
250
0
Neg
Pancreatic leak
NED
NR
Khithani
2009
F
60
PDAC
CT
NR
NR
Jaundice, pain
SPDS, GR
Resected
BL
BL
N/A
JT
NR
NR
NR
NR
NR
NED
NR
 
2009
F
57
PDAC
CT
NR
NR
Incidental finding
SPDS, GR
Resected
BL
BL
N/A
JT
NR
NR
NR
NR
NR
NED
NR
Rutkoski
2008
F
49
PDAC
CT, US, MRCP
5
Lap
Pain, nausea/vomiting, jaundice
SPDS
Spared
CC
CC
BL
NR
NR
NR
1
Neg
NR
DOD
9
Theodoropoulos
2012
F
53
PDAC
CT
14
Open
Pain
SPDS, BL
Spared
CC distal to J-J
CC distal to J-J
CC distal to J-J
NR
NR
NR
1
Neg
NR
NED
NR
Nikfarjam
2009
F
46
FDBDF
CT, PTC
3
Lap
Jaundice
SPDS, GR
Resected
BL
BL
N/A
NR
480
100
N/A
N/A
NR
N/A
12
 
2009
F
72
FDBDF
CT, PTC
5
Open
Jaundice, weight loss
SPDS, GR
Resected
BL
BL
N/A
NR
300
950
N/A
N/A
NR
N/A
12
Peng
2018
  
PDAC
CT, Perc
 
Open
 
SPDS
Spared
AL
AL
CC
NR
  
NR
Pos
NR
DOD
81
    
PDAC
CT
 
Open
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
NR
Pos
NR
DOD
50
    
IPMN
CT, PTC
 
Lap
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
NR
Neg
NR
DOD
18
    
PDAC
CT
 
NR
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
NR
Pos
NR
DOD
37
    
PDAC
CT, PTC
 
Open
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
NR
Pos
NR
AWD
53
    
CP
CT, PTC
 
Open
 
SPDS, GR, GJ
Resected
BL
BL
N/A
NR
  
N/A
N/A
NR
N/A
NR
    
Duodenal Ca
CT, PTC, Endo
 
Open
 
SPDS
Spared
BL
BL
BL
NR
  
NR
Neg
NR
AWD
57
    
PDAC
CT, Perc
 
Lap
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
NR
Neg
NR
AWD
34
    
CP
CT, PTC, Endo
 
Open
 
SPDS, GR
Resected
BL
BL
N/A
NR
  
N/A
N/A
NR
N/A
NR
    
PDAC
CT, PTC
 
Open
 
SPDS, GR, Spleen
Resected
BL
BL
N/A
NR
  
NR
Neg
NR
DOD
16
    
PDAC
CT, PTC
 
Lap
 
Pancreas, GR
Resected
BL
BL
N/A
NR
  
NR
Neg
NR
DOD
27
 
Mean
 
64
  
10
        
361
500
     
Current report
2015
F
63
PDAC
CT
12
Open
Pain, nausea/vomiting
SPDS, BL
Spared
CC
CC
CC
GT
765
400
2
Neg
Pancreatic fistula
DOD
23
NR not reported, N/A not applicable, RYGB Roux-en-Y Gastric Bypass, PDAC pancreatic ductal adenocarcinoma, NET neuroendocrine tumor, FDBDF focal distal bile duct fibrosis, CP chronic pancreatitis, CT computed tomography, US ultrasound, MRCP magnetic resonance cholangiopancreatography, PTC percutaneous transhepatic cholangiography, Perc percutaneous biopsy, Endo endoscopic biopsy, Lap laparoscopic, NR not reported, SPDS standard pancreaticoduodenectomy specimen (pancreatic head, duodenum, antrum, common bile duct, and gallbladder, if present), PPPDS pylorus-preserving pancreaticoduodenectomy specimen (pancreatic head, distal duodenum, common bile duct), GR gastric remnant, BL biliopancreatic limb, CC common channel, AL alimentary limb, jej-jej jejunojejunostomy, JT feeding jejunostomy tube placed, GT feeding gastrostomy tube, ECF enterocutaneous fistula, NED no evidence of disease, DOD dead of disease, AWD alive with disease
Table 2
Patient, diagnostic, and pathologic characteristics of post-RYGB patients undergoing pancreaticoduodenectomy in reviewed cases (N = 26)
Parameter
Proportion or median
Percentage (%) or IQR
Patient demographics
 Sex (female)
12/15
80
 Age (years)
54
52–61
 Years from RYGB*
5
2–10
Presenting complaint**
 Pain
18/26
69.2
 Jaundice
14/26
53.8
 Weight loss
9/26
34.6
 Nausea/vomiting
5/26
19.2
 Incidental finding
4/26
15.4
 Diarrhea
2/26
7.7
 Fever/chills
1/26
3.9
Preoperative diagnostic modality**
 CT
26/26
100
 PTC
9/26
34.6
 Percutaneous biopsy
3/26
11.5
 Endoscopic biopsy
2/26
7.7
 US
1/26
3.9
 MRCP
1/26
3.9
Pathologic diagnosis
 PDAC
14/26
53.8
 NET
3/26
11.5
 CP
3/26
11.5
 FDBDF
2/26
7.7
 IPMN
1/26
3.9
 Duodenal Ca
1/26
3.9
 Ampullary Ca
1/26
3.9
IQR interquartile range, RYGB Roux-en-Y Gastric Bypass, PDAC pancreatic ductal adenocarcinoma, NET neuroendocrine tumor, FDBDF focal distal bile duct fibrosis, CP chronic pancreatitis, IPMN intraductal papillary mucinous neoplasm, CT computed tomography, US ultrasound, MRCP magnetic resonance cholangiopancreatography, PTC percutaneous transhepatic cholangiography
*Only 11 cases with reported RYGB details
**Possible for one patient to have multiple presenting symptoms or diagnostic modalities
Table 3
Operative and post-operative characteristics of post-RYGB patients undergoing pancreaticoduodenectomy in reviewed cases (N = 26)
Parameter
Proportion
Percentage (%)
Pancreatic resection performed
 Pancreaticoduodenectomy
24/26
92.3
 Pylorus-preserving pancreaticoduodenectomy
1/26
3.8
 Total pancreatectomy
1/26
3.8
Resection specimen (in addition to standard PD specimen)
 Gastric remnant
18/26
69.2
 Old biliopancreatic limb
3/26
11.5
Reconstruction of biliopancreatic drainage
 Biliopancreatic limb
21/26
73.1
 New limb from common channel
3/26
19.2
 New limb from alimentary limb
1/26
3.8
 Common channel (limb in continuity)
1/26
3.8
Drainage of gastric remnant
 Biliopancreatic limb
4/8
50
 New limb from common channel
3/8
37.5
 Common channel (limb in continuity)
1/8
12.5
Enteral feeding access
 Gastrostomy tube
3/26
11.5
 Jejunostomy tube
2/26
7.7
Oncologic outcome
 NED
10/21
84.6
 DOD
8/21
7.7
 AWD
3/21
7.7
 Median follow-up (months)
17/26
27
PD pancreaticoduodenectomy, IQR interquartile range, NED no evidence of disease, DOD dead of disease, AWD alive with disease

Discussion

Obesity is a known risk factor for pancreatic cancer [1, 2]. As in our patient, the diagnosis of a resectable pancreatic head mass requires a PD, classically involving en bloc resection of the pancreatic head, distal stomach and duodenum, common bile duct, and gallbladder. Reconstruction is typically achieved by creation of a pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy, in series. However, given the anatomical alterations, post-PD reconstruction requires greater forethought in the post-RYGB population. Although infrequently reported, these procedures can be longer in duration with a greater potential for morbidity. All potential reconstruction options found in the literature are summarized in Fig. 2. Patient selection and preoperative planning to identify resectable disease are paramount [22].
Classically, the RYGB reconstruction involves creating an anastomosis of the jejunal alimentary limb to the gastric pouch, which is connected to a separate biliopancreatic limb. This reconstructed anatomy produces both restrictive and malabsorptive components for weight loss. A subsequent PD requires reconstruction of biliary and pancreatic drainage which had previously been achieved by the biliopancreatic limb. If there remains sufficient length on this limb, most authors recommend using the distal jejunal segment of this limb to accomplish drainage [12]. In certain cases, the entire biliopancreatic limb may need to be resected, requiring construction of a new limb. The source of this new biliopancreatic limb may arise from the old common channel distal to the jejunojejunostomy (Fig. 2a) or from the amputated alimentary limb, the distal part of which becomes utilized for a hepaticojejunostomy and pancreaticojejunostomy (Fig. 2b). In both circumstances, a separate jejunojejunal anastomosis will need to occur.
If the gastric remnant is not resected, drainage of this channel must be factored into the reconstruction. The more commonly reported reconstruction consists of using a new limb from the old common channel for hepaticojejunostomy, pancreaticojejunostomy, and remnant gastrojejunostomy (Fig. 2c). Our patient underwent a PD with resection of the old biliopancreatic limb, sparing the gastric remnant and placement of a feeding gastrostomy tube (pre-operative albumin 2.6 g/dL). We recreated the biliopancreatic limb from the prior common channel. Since the gastric remnant was left in situ, we performed a jejuno-gastric remnant anastomosis in series with this same limb. Alternatively, another author reported using the old biliopancreatic limb for the remnant gastrojejunostomy while raising a new limb from the old common channel for the hepaticojejunostomy and pancreaticojejunostomy (Fig. 2d) [19]. While physiologically appropriate, this does increase the number of anastomoses and possibility of morbidity. Of interest, one author reported construction of a hepaticojejunostomy and pancreaticojejunostomy with the common channel far distal to the jejunojejunostomy and in continuity with the gastric pouch and alimentary limb (Fig. 2e) [20]. This is inadvisable, as there is risk for reflux of enteric contents into the biliary tree, increasing the incidence of cholangitis [12]. Each of these reconstruction methods reflects surgeon preference, as well as anatomic considerations posed by individual patients.
Though less commonly performed in the reviewed cases (30.8%), there may be advantages to retaining the gastric remnant during PD in the post-RYGB patient including retained physiologic function, nutritional support, and ease of future diagnostic and therapeutic interventions. Since the first gastric bypass reported by Ito and Mason in 1967, interest in gastrointestinal tract physiologic changes brought on by altered surgical anatomy persists [23]. Particular focus was paid to the importance of the excluded stomach (remnant) for motility and secretory function, plus the impact of surgical discontinuity of the gastric pouch. Printen et al. and Mason et al. published studies in which pre- and post-operative gastric pH and secretions were found to be identical [21, 24]. Both studies pointed to retention of vagal innervation to the gastric remnant. Given that motor migratory complex (MMC) initiates mainly from the interstitial cells of Cajal at the gastric antrum, peristalsis remains present in the gastric remnant. The propulsion of gastric, biliary, and pancreatic secretions into the common channel after bypass is evidence of this [25].
The gastric remnant also retains importance in the body’s endocrine and exocrine functions in the post-RYGB anatomy. The increase in levels of incretin hormones in the post-RYGB, such as glucagon-like peptide-1 (GLP—1) and gastric inhibitory peptide (GIP), is well studied [26, 27]. Severe hypogylcemia after RYGB is an increasingly recognized complication, possibly due to hyperinsulinemia and β-cell proliferation from increased GLP-1 activity, or failure of islet cell regression in diabetic patients post-RYGB [28]. McLaughlin et al. successfully treated medically refractory hypoglycemia after RYGB with enteral feeds through a gastrostomy tube placed in the gastric remnant. This corrected post-surgical derangements in glucose, insulin, GLP-1, glucagon, and GIP after oral food intake [29].
Additionally, 16% of partial gastrectomy patients develop B12 deficiency and this rate increases with elapsed-time post-surgery, with some patients presenting with B12 deficiency 10 years or more after partial gastrectomy [30, 31]. This effect is, in part, due to both the restrictive and malabsorptive aspects of the procedure. The early satiety induced by gastric restriction leads to reduction in hydrochloric acid and pepsin production. Reduction of available B12 from food and decreased exposure to intrinsic factor (IF) producing cells subsequently leads to B12 malabsorption [32]. B12 deficiency can have profound implications on overall health, anemia, and neurologic disorders [33]. Recently, Sala et al. demonstrated that post-RYGB risk of B12 deficiency may also be the result of changes in upregulation of B12 pathway-encoding genes [32]. The gastric remnant may also be capable of reasserting its function for intrinsic factor production, as well as modulating secondary measures of intestinal B12 absorption via increased production of transcobolamin II, which binds B12 after its release from IF in the ileum [32].
Delayed gastric emptying (DGE) is a common post-operative complication of PD, occurring in 15–40% of patients [34, 35]. Suspected causes of DGE include removal of the motilin-secreting duodenum, gastric irritation from bile, and interruption of the myoneural pathways in the bowel wall [36]. Furthermore, DGE has been associated with deep space infection and leak, although causal relationships remain poorly defined [37]. Regardless of etiology, DGE interferes with resumption of normal diet and post-operative nutrition. In the post-RYGB patient, this complication may be amplified due to the altered physiology. A study by Dutra et al. on Wistar rats previously showed that increased length of the biliopancreatic limb could serve as a functional barrier to gastric emptying while offering no advantages in preventing enterogastric reflux [38]. Gustavsson et al. analyzed outcomes of 234 patients who underwent total or subtotal gastrectomy with Roux-en-Y reconstruction, demonstrating that those with gastric dysmotility had longer roux-limbs (mean 41 cm), and shortening these limbs improved symptoms [39]. Additional studies of dysmotility after RYGB focus on reconstruction of intestinal anatomy and disruption of MMCs, displacement of the native pacemaker cells of the gut by slower ectopic signals, and changes in the metabolic and endocrine regulation of these events [40]. Preservation of the gastric remnant with subsequent reconstruction in this patient population may allow for improved physiologic parameters, and diagnostic and therapeutic interventions.
Intolerance to oral intake is multi-factorial in the PD-RYGB population and can sufficiently compromise patient nutrition, requiring further intervention for enteral supplementation. An intact gastric remnant provides the opportunity to leave a remnant gastrostomy tube for post-operative decompression and enteral nutrition post-PD [41]. In our patient, we placed a feeding gastrostomy tube in the gastric remnant, as malnutrition is associated with adverse outcomes following PD, especially in a patient who has already had significant weight loss and hypoalbuminemia [42, 43]. These complications include sepsis, impaired wound healing, and pancreatic fistula formation [4446]. A recent systematic analysis of different enteral routes of nutrition (15 articles, 3474 patients) found that gastrojejunostomy feeding was associated with the shortest hospital stay (mean 15 days) and lowest incidence of delayed gastric emptying (6%) [47]. Barbour et al. published an experience with five patients requiring pancreatic resections after RYGB in which a gastrostomy tube in the gastric remnant was successfully used for decompression and, later, to supplement with enteral nutrition [41]. This may be particularly significant in the post-RYGB patient as hypoalbuminemia (< 3.5 mg/dL) may occur in up to 13% [48]. Remnant gastrojejunostomy placement may help overcome these issues.
Preservation of the gastric remnant also aids in post-PD diagnostic and therapeutic intervention. Performing ERCP in the altered anatomy post-PD can be technically challenging even with an intact stomach. Many endoscopists favor anterograde EUS access for pancreatic duct interventions post-PD. Such interventions may be difficult, from a small gastric pouch. Chalal et al. demonstrated only a 51% success rate in 88 ERCPs performed in post-PD patients at the Mayo Clinic (2002–2005) [49]. Laparoscopic-assisted ERCP to access the remnant stomach, as opposed to the jejunum or gastric pouch, may provide a number of advantages, especially in terms of supporting access in a position similar to native anatomy [50]. Several investigators described success with EUS access of the remnant stomach to allow for laparoscopic-assisted ERCP through the remnant in post-Roux-en-Y anatomy [51].
While reversal of RYGB is an uncommon procedure, the related literature demonstrates improvement in post-operative morbidities related to the post-RYGB anatomy, lending support to the concept that the gastric remnant retains much of its physiologic function [52, 53]. In cases in which the post-RYGB patient develops severe complications (acute hypoglycemia, weight regain, intractable diarrhea, extreme dumping syndrome, cachexia), reversal of the bypass to normal anatomy commonly leads to resolution of symptoms [52]. Vilallonga et al. published an experience with 20 patients in which they describe laparoscopic reversal of RYGB with resolution of most complications, although few patients did develop gastroesophageal reflux disease (three patients) and diarrhea (one patient), secondary to damage of the vagus nerves [54]. Similarly, Pernar et al. showed resolution of the predominant symptoms in 15 of 19 patients, including 6 weaned from total parenteral nutrition (TPN). Given that the gastric remnant retains its function, this procedure remains an option, though it should only be considered in select patients.
Despite the benefits of leaving the gastric remnant in situ, there may be technical advantages to resecting the gastric remnant en bloc with the specimen [5557]. First, it obviates the need for a jejuno-gastric remnant anastomosis and associated potential complications. However, an important consideration, a prospectively collected, multicenter study by Smith et al. of nearly 4500 gastric bypass patients, found only 1% clinically significant gastrojejunostomy leak rate [57]. In turn, other recent series report anastomotic stricture rates between 4.8 and 7.3% [55, 56]. Therefore, by resecting the remnant and avoiding additional anastomoses, the surgeon may simplify the subsequent reconstruction while avoiding potential morbidity. In contrast, preserving the gastric remnant may also allow for future development of bleeding, ulceration, or undetected malignancy, although the overall risk of developing gastric and esophageal malignancies is reportedly rare in the post-RYGB patient [5860].
This systematic review has limitations. Few publications exist interrogating this particular area; therefore, there remains a paucity of data with which to develop clear, evidence-based guidelines for reconstruction options. Indeed, with both the increasing incidence of pancreatic cancer and number of patients undergoing bariatric procedures, this clinical scenario will become more prevalent, making discussions of the surgical options more frequent and relevant. Furthermore, gastric remnant preservation, while currently performed less frequently, may be advantageous from a multidisciplinary standpoint, but clearly requires further investigation [61]. Although not discussed, decisions regarding preoperative diagnostic modalities or perioperative neoadjuvant and adjuvant treatments for this unique, but expanding, patient population deserves further review.

Conclusions

Pancreaticoduodenectomy after Roux-en-Y gastric bypass is a complex procedure that is rarely performed. Varying practice patterns reflect the complexity of the surgery and diversity of surgeon preference. Few publications exist to develop recommendations, yet there is a growing need to provide evidence for the safest and most effective method of resection and reconstruction in this growing population. Regardless of reconstruction used, the most important goal should be definitive resection (R0), followed by consideration for the patient’s future quality of life and further treatment.

Acknowledgements

The authors would like to acknowledge the late Dr. Andres E. Castellanos, MD, FACS, whose leadership and experience within our department was vital to the development of the bariatric surgery program and resident education.

Funding

Funding for manuscript publication is provided by the Drexel University College of Medicine Departments of Surgery and Medicine.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Because any included data was de-identified, this review was exempt from review by the IRB at Drexel University College of Medicine.
Consent was obtained from patient’s next of kin, though no identifiable data was included in this manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Flegal KM, Carroll MD, Ogden CL. Prevalence and trends in obesity among US adults, 1998-2008. JAMA. 2010;303(3):235–41.CrossRefPubMed Flegal KM, Carroll MD, Ogden CL. Prevalence and trends in obesity among US adults, 1998-2008. JAMA. 2010;303(3):235–41.CrossRefPubMed
2.
Zurück zum Zitat Rebours V, Gaujoux S, d'Assignies G, Sauvanet A, Ruszniewski P, Lévy P, et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res. 2015;21(15):3522–8.CrossRefPubMed Rebours V, Gaujoux S, d'Assignies G, Sauvanet A, Ruszniewski P, Lévy P, et al. Obesity and fatty pancreatic infiltration are risk factors for pancreatic precancerous lesions (PanIN). Clin Cancer Res. 2015;21(15):3522–8.CrossRefPubMed
3.
Zurück zum Zitat Nimptsch K, Pischon T. Body fatness, related biomarkers and cancer risk: epidemiological perspective. Horm Mol Biol Clin Investig. 2015;22(2):39–51.PubMed Nimptsch K, Pischon T. Body fatness, related biomarkers and cancer risk: epidemiological perspective. Horm Mol Biol Clin Investig. 2015;22(2):39–51.PubMed
4.
Zurück zum Zitat O'Brien PE, McPhail T, Chaston TB, Dixon JB. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16(8):1032–40.CrossRefPubMed O'Brien PE, McPhail T, Chaston TB, Dixon JB. Systematic review of medium-term weight loss after bariatric operations. Obes Surg. 2006;16(8):1032–40.CrossRefPubMed
5.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMed Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.CrossRefPubMed
6.
Zurück zum Zitat Korenkov M, Sauerlan S, Junginger T. Surgery for obesity. Curr Opin Gastroenterol. 2005;21(6):679–83.PubMed Korenkov M, Sauerlan S, Junginger T. Surgery for obesity. Curr Opin Gastroenterol. 2005;21(6):679–83.PubMed
7.
Zurück zum Zitat Khashab MA, Okolo PI. Accessing the pancreatobiliary limb and ERCP in the bariatric patient. Gastrointest Endosc Clin N Am. 2011;21(2):305–13.CrossRefPubMed Khashab MA, Okolo PI. Accessing the pancreatobiliary limb and ERCP in the bariatric patient. Gastrointest Endosc Clin N Am. 2011;21(2):305–13.CrossRefPubMed
8.
Zurück zum Zitat Schreiner MA, Chang L, Gluck M, Irani S, Gan S, Brandabur JJ, et al. Laparoscopy-assisted versus balloon enteroscopy-assisted ERCP in bariatric post-Roux-en-Y gastric bypass patients. Gastrointest Endosc. 2012;75(4):748–56.CrossRefPubMed Schreiner MA, Chang L, Gluck M, Irani S, Gan S, Brandabur JJ, et al. Laparoscopy-assisted versus balloon enteroscopy-assisted ERCP in bariatric post-Roux-en-Y gastric bypass patients. Gastrointest Endosc. 2012;75(4):748–56.CrossRefPubMed
9.
Zurück zum Zitat Lopes TL, Clements RH, Wilcox CM. Laparoscopy-assisted ERCP: experience of a high-volume bariatric surgery center (with video). Gastrointest Endosc. 2009;70(6):1254–9.CrossRefPubMed Lopes TL, Clements RH, Wilcox CM. Laparoscopy-assisted ERCP: experience of a high-volume bariatric surgery center (with video). Gastrointest Endosc. 2009;70(6):1254–9.CrossRefPubMed
10.
Zurück zum Zitat Saleem A, Levy MJ, Petersen BT, Que FG, Baron TH. Laparoscopic-assisted ERCP in Roux-en-Y gastric bypass (RYGB) surgery patients. J Gastrointest Surg. 2012;16(1):203–8.CrossRefPubMed Saleem A, Levy MJ, Petersen BT, Que FG, Baron TH. Laparoscopic-assisted ERCP in Roux-en-Y gastric bypass (RYGB) surgery patients. J Gastrointest Surg. 2012;16(1):203–8.CrossRefPubMed
11.
Zurück zum Zitat Baron TH, Song LM, Ferreira LE, Smyrk TC. Novel approach to therapeutic ERCP after long-limb Roux-en-Y gastric bypass surgery using transgastric self-expandable metal stents: experimental outcomes and first human case study (with videos). Gastrointest Endosc. 2012;75(6):1258–63.CrossRefPubMed Baron TH, Song LM, Ferreira LE, Smyrk TC. Novel approach to therapeutic ERCP after long-limb Roux-en-Y gastric bypass surgery using transgastric self-expandable metal stents: experimental outcomes and first human case study (with videos). Gastrointest Endosc. 2012;75(6):1258–63.CrossRefPubMed
12.
Zurück zum Zitat Hatzaras I, Sachs TE, Weiss M, Wolfgang CL, Pawlik T. Pancreaticoduodenectomy after bariatric surgery: challenges and available techniques for reconstruction. J Gastrointest Surg. 2014;18(4):869–77.CrossRefPubMed Hatzaras I, Sachs TE, Weiss M, Wolfgang CL, Pawlik T. Pancreaticoduodenectomy after bariatric surgery: challenges and available techniques for reconstruction. J Gastrointest Surg. 2014;18(4):869–77.CrossRefPubMed
13.
Zurück zum Zitat Helmick R, Singh R, Welshhans J, Fegelman EJ, Shahid H. Pancreaticoduodenectomy after Roux-en-Y gastric bypass: a single institution retrospective series. IJHPD. 2013;3:17–21.CrossRef Helmick R, Singh R, Welshhans J, Fegelman EJ, Shahid H. Pancreaticoduodenectomy after Roux-en-Y gastric bypass: a single institution retrospective series. IJHPD. 2013;3:17–21.CrossRef
14.
Zurück zum Zitat Swain JM, Adams RB, Farnell MB, Que FG, Sarr MG. Gastric and pancreatoduodenal resection for malignant lesions after previous gastric bypass--diagnosis and methods of reconstruction. Surg Obes Relat Dis. 2010;6(6):670–5.CrossRefPubMed Swain JM, Adams RB, Farnell MB, Que FG, Sarr MG. Gastric and pancreatoduodenal resection for malignant lesions after previous gastric bypass--diagnosis and methods of reconstruction. Surg Obes Relat Dis. 2010;6(6):670–5.CrossRefPubMed
15.
Zurück zum Zitat de la Cruz-Muñoz N, Hartnett S, Sleeman D. Laparoscopic pancreatoduodenectomy after laparoscopic gastric bypass. Surg Obes Relat Dis. 2011;7(3):326–7.CrossRefPubMed de la Cruz-Muñoz N, Hartnett S, Sleeman D. Laparoscopic pancreatoduodenectomy after laparoscopic gastric bypass. Surg Obes Relat Dis. 2011;7(3):326–7.CrossRefPubMed
16.
Zurück zum Zitat Peng JS, Corcelles R, Choong K, Gandhi N, Walsh RM, Hardacre JM, et al. Pancreatoduodenectomy after Roux-en-Y gastric bypass: technical considerations and outcomes. HPB (Oxford). 2018;20(1):34–40.CrossRefPubMed Peng JS, Corcelles R, Choong K, Gandhi N, Walsh RM, Hardacre JM, et al. Pancreatoduodenectomy after Roux-en-Y gastric bypass: technical considerations and outcomes. HPB (Oxford). 2018;20(1):34–40.CrossRefPubMed
17.
Zurück zum Zitat Khithani AS, Curtis DE, Galanopoulos C, Jeyarajah DR. Pancreaticoduodenectomy after a Roux-en-Y gastric bypass. Obes Surg. 2009;19(6):802–5.CrossRefPubMed Khithani AS, Curtis DE, Galanopoulos C, Jeyarajah DR. Pancreaticoduodenectomy after a Roux-en-Y gastric bypass. Obes Surg. 2009;19(6):802–5.CrossRefPubMed
18.
Zurück zum Zitat Nikfarjam M, Staveley-O'Carroll KF, Kimchi ET, Hardacre JM. Pancreaticoduodenectomy in patients with a history of Roux-en Y gastric bypass surgery. Journal of the Pancreas. 2009;10(2):169–73.PubMed Nikfarjam M, Staveley-O'Carroll KF, Kimchi ET, Hardacre JM. Pancreaticoduodenectomy in patients with a history of Roux-en Y gastric bypass surgery. Journal of the Pancreas. 2009;10(2):169–73.PubMed
19.
Zurück zum Zitat Rutkoski JD, Gagne DJ, Volpe C, Papasavas PK, Hayetian F, Caushaj PF. Pancreaticoduodenectomy for pancreatic cancer after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2008;4(4):552–4.CrossRefPubMed Rutkoski JD, Gagne DJ, Volpe C, Papasavas PK, Hayetian F, Caushaj PF. Pancreaticoduodenectomy for pancreatic cancer after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2008;4(4):552–4.CrossRefPubMed
20.
Zurück zum Zitat Theodoropolous I, Franco C, Gervasoni JE. Pancreaticoduodenectomy for pancreatic carcinoma after complicated open Roux-en-Y gastric bypass surgery: an alternative approach to reconstruction. Surg Obes Relat Dis. 2012;8(5):648–50.CrossRef Theodoropolous I, Franco C, Gervasoni JE. Pancreaticoduodenectomy for pancreatic carcinoma after complicated open Roux-en-Y gastric bypass surgery: an alternative approach to reconstruction. Surg Obes Relat Dis. 2012;8(5):648–50.CrossRef
21.
Zurück zum Zitat Mason EE, Munns JR, Kealey GP, Wangler R, Clarke WR, Cheng HF, et al. Effect of gastric bypass on gastric secretion. Am J Surg. 1976;131(2):162–8.CrossRefPubMed Mason EE, Munns JR, Kealey GP, Wangler R, Clarke WR, Cheng HF, et al. Effect of gastric bypass on gastric secretion. Am J Surg. 1976;131(2):162–8.CrossRefPubMed
22.
Zurück zum Zitat Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.CrossRefPubMedPubMedCentral Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Printen KJ, Owensby M. Vagal innervation of the bypassed stomach following gastric bypass. Surgery. 1978;84(4):455–6.PubMed Printen KJ, Owensby M. Vagal innervation of the bypassed stomach following gastric bypass. Surgery. 1978;84(4):455–6.PubMed
25.
Zurück zum Zitat Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–85.CrossRefPubMed Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–85.CrossRefPubMed
26.
Zurück zum Zitat Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, et al. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;48(11):2236–40.CrossRefPubMed Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, et al. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;48(11):2236–40.CrossRefPubMed
27.
Zurück zum Zitat Borg CM, Le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93(2):210–5.CrossRefPubMed Borg CM, Le Roux CW, Ghatei MA, Bloom SR, Patel AG, Aylwin SJ. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93(2):210–5.CrossRefPubMed
28.
Zurück zum Zitat Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249–54.CrossRefPubMed Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med. 2005;353(3):249–54.CrossRefPubMed
29.
Zurück zum Zitat McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab. 2010;95(4):1851–5.CrossRefPubMed McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab. 2010;95(4):1851–5.CrossRefPubMed
30.
Zurück zum Zitat Hu Y, Kim HI, Hyung WJ, Lee JH, Kim YM, Noh SH. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors. Ann Surg. 2013;258(6):970–5.CrossRefPubMed Hu Y, Kim HI, Hyung WJ, Lee JH, Kim YM, Noh SH. Vitamin B(12) deficiency after gastrectomy for gastric cancer: an analysis of clinical patterns and risk factors. Ann Surg. 2013;258(6):970–5.CrossRefPubMed
31.
Zurück zum Zitat Weir DG, Temperley IJ, Gatenby PBB. Vitamin B12 deficiency following partial gastrectomy. Ir J Med Sci. 1966;41(3):97–102.CrossRef Weir DG, Temperley IJ, Gatenby PBB. Vitamin B12 deficiency following partial gastrectomy. Ir J Med Sci. 1966;41(3):97–102.CrossRef
32.
Zurück zum Zitat Sala P, Belarmino G, Torrinhas RS, Machado NM, Fonseca DC, Ravacci GR, et al. Gastrointestinal transcriptomic response of metabolic vitamin B12 pathways in Roux-en-Y gastric bypass. Clin Transl Gastroenterol. 2017;8(1):e212.CrossRefPubMedPubMedCentral Sala P, Belarmino G, Torrinhas RS, Machado NM, Fonseca DC, Ravacci GR, et al. Gastrointestinal transcriptomic response of metabolic vitamin B12 pathways in Roux-en-Y gastric bypass. Clin Transl Gastroenterol. 2017;8(1):e212.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Nielse MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body’s cells--a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol. 2012;9(6):345–54.CrossRef Nielse MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body’s cells--a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol. 2012;9(6):345–54.CrossRef
34.
Zurück zum Zitat Mon RA, Cullen JJ. Standard Roux-en-Y gastrojejunostomy vs. “uncut” Roux-en-Y gastrojejunostomy: a matched cohort study. J Gastrointest Surg. 2000;4(3):298–303.CrossRefPubMed Mon RA, Cullen JJ. Standard Roux-en-Y gastrojejunostomy vs. “uncut” Roux-en-Y gastrojejunostomy: a matched cohort study. J Gastrointest Surg. 2000;4(3):298–303.CrossRefPubMed
35.
Zurück zum Zitat Fabre JM, Burgel JS, Navarro F, Boccarat G, Lemoine C, Domergue J. Delayed gastric emptying after pancreaticoduodenectomy and pancreaticogastrostomy. Eur J Surg. 1999;165(6):560–5.CrossRefPubMed Fabre JM, Burgel JS, Navarro F, Boccarat G, Lemoine C, Domergue J. Delayed gastric emptying after pancreaticoduodenectomy and pancreaticogastrostomy. Eur J Surg. 1999;165(6):560–5.CrossRefPubMed
37.
Zurück zum Zitat Parmar MD, Sheffield KM, Vargas GM, Pitt HA, Kilbane EM, Hall BL, et al. Factors associated with delayed gastric emptying after pancreaticoduodenectomy. HPB (Oxford). 2013;15(10):763–72.CrossRef Parmar MD, Sheffield KM, Vargas GM, Pitt HA, Kilbane EM, Hall BL, et al. Factors associated with delayed gastric emptying after pancreaticoduodenectomy. HPB (Oxford). 2013;15(10):763–72.CrossRef
38.
Zurück zum Zitat Dutra RA, Araújo WM, Andrade JI. The effects of Roux-en-Y limb length on gastric emptying and enterogastric reflux in rats. Acta Cir Bras. 2008;23(2):179–83.CrossRefPubMed Dutra RA, Araújo WM, Andrade JI. The effects of Roux-en-Y limb length on gastric emptying and enterogastric reflux in rats. Acta Cir Bras. 2008;23(2):179–83.CrossRefPubMed
39.
Zurück zum Zitat Gustavsson S, ilstrup DM, Morrison P, Kelly KA. Roux-en-Y stasis syndrome after gastrectomy. Am J Surg. 1988;155(3):490–4.CrossRefPubMed Gustavsson S, ilstrup DM, Morrison P, Kelly KA. Roux-en-Y stasis syndrome after gastrectomy. Am J Surg. 1988;155(3):490–4.CrossRefPubMed
40.
Zurück zum Zitat Quercia I, Dutia R, Kotler DP, Belsley S, Laferrère B. Gastrointestinal changes after bariatric surgery. Diabetes Metab. 2014;40(2):87–94.CrossRefPubMed Quercia I, Dutia R, Kotler DP, Belsley S, Laferrère B. Gastrointestinal changes after bariatric surgery. Diabetes Metab. 2014;40(2):87–94.CrossRefPubMed
41.
Zurück zum Zitat Barbour JR, Thomas BN, Morgan KA, Byrne TK, Adams DB. The practice of pancreatic resection after Roux-en-Y gastric bypass. Am Surg. 2008;74(8):729–34.PubMed Barbour JR, Thomas BN, Morgan KA, Byrne TK, Adams DB. The practice of pancreatic resection after Roux-en-Y gastric bypass. Am Surg. 2008;74(8):729–34.PubMed
42.
Zurück zum Zitat Gleeson EM, Shaikh MF, Shewokis PA, Clarke JR, Meyers WC, Pitt HA, et al. Whipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database. Surgery. 2016;160(5):1279–87.CrossRefPubMed Gleeson EM, Shaikh MF, Shewokis PA, Clarke JR, Meyers WC, Pitt HA, et al. Whipple-ABACUS, a simple, validated risk score for 30-day mortality after pancreaticoduodenectomy developed using the ACS-NSQIP database. Surgery. 2016;160(5):1279–87.CrossRefPubMed
43.
Zurück zum Zitat Gleeson EM, Clarke JR, Morano WF, Shaikh MF, Bowne WB, Pitt HA. Patient-specific predictors of failure to rescue after pancreaticoduodenectomy. HPB. 2018;In-press. Gleeson EM, Clarke JR, Morano WF, Shaikh MF, Bowne WB, Pitt HA. Patient-specific predictors of failure to rescue after pancreaticoduodenectomy. HPB. 2018;In-press.
44.
Zurück zum Zitat M FA, Feliciano DV, Andrassy RJ, AH MA, Booth FV, Morgenstein-Wagner TB, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. Ann Surg. 1992;216(2):172–83.CrossRef M FA, Feliciano DV, Andrassy RJ, AH MA, Booth FV, Morgenstein-Wagner TB, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. Ann Surg. 1992;216(2):172–83.CrossRef
45.
Zurück zum Zitat Zaloga GP, Bortenschlager L, Black KW, Prielipp R. Immediate postoperative enteral feeding decreases weight loss and improves wound healing after abdominal surgery in rats. Crit Care Med. 1992;20(1):115–8.CrossRefPubMed Zaloga GP, Bortenschlager L, Black KW, Prielipp R. Immediate postoperative enteral feeding decreases weight loss and improves wound healing after abdominal surgery in rats. Crit Care Med. 1992;20(1):115–8.CrossRefPubMed
46.
Zurück zum Zitat Aranha GV, Aaron JM, Shoup M, Pickleman J. Current management of pancreatic fistula after pancreaticoduodenectomy. Surgery. 2006;140(4):561–8.CrossRefPubMed Aranha GV, Aaron JM, Shoup M, Pickleman J. Current management of pancreatic fistula after pancreaticoduodenectomy. Surgery. 2006;140(4):561–8.CrossRefPubMed
47.
Zurück zum Zitat Gerritsen A, Besselink MG, Gouma DJ, Steenhagen E, Borel Rinkes IH, Molenaar IQ. Systematic review of five feeding routes after pancreatoduodenectomy. Br J Surg. 2013;100(5):589–98.CrossRefPubMed Gerritsen A, Besselink MG, Gouma DJ, Steenhagen E, Borel Rinkes IH, Molenaar IQ. Systematic review of five feeding routes after pancreatoduodenectomy. Br J Surg. 2013;100(5):589–98.CrossRefPubMed
48.
Zurück zum Zitat Faintuch J, Matsuda M, Cruz ME, Silva MM, Teivelis MP, Garrido AB, et al. Severe protein-calorie malnutrition after bariatric procedures. Obes Surg. 2004;14(2):175–81.CrossRefPubMed Faintuch J, Matsuda M, Cruz ME, Silva MM, Teivelis MP, Garrido AB, et al. Severe protein-calorie malnutrition after bariatric procedures. Obes Surg. 2004;14(2):175–81.CrossRefPubMed
49.
Zurück zum Zitat Chalal P, Baron TH, Topazian MD, Petersen BT, Levy MJ, Gostout CJ. Endoscopic retrograde cholangiopancreatography in post-Whipple patients. Endoscopy. 2006;38(12):1241–5.CrossRef Chalal P, Baron TH, Topazian MD, Petersen BT, Levy MJ, Gostout CJ. Endoscopic retrograde cholangiopancreatography in post-Whipple patients. Endoscopy. 2006;38(12):1241–5.CrossRef
50.
Zurück zum Zitat Ross AS. Techniques for performing ERCP in Roux-en-Y gastric bypass patients. Gastroenterol Hepatol (NY). 2012;8(6):390–2. Ross AS. Techniques for performing ERCP in Roux-en-Y gastric bypass patients. Gastroenterol Hepatol (NY). 2012;8(6):390–2.
51.
Zurück zum Zitat Attam R, Leslie D, Arain MA, Freeman ML, Ikramuddin S. EUS-guided sutured gastropexy for transgastric ERCP (ESTER) in patients with Roux-en-Y gastric bypass: a novel, single-session, minimally invasive approach. Endoscopy. 2015;47(7):646–9.CrossRefPubMed Attam R, Leslie D, Arain MA, Freeman ML, Ikramuddin S. EUS-guided sutured gastropexy for transgastric ERCP (ESTER) in patients with Roux-en-Y gastric bypass: a novel, single-session, minimally invasive approach. Endoscopy. 2015;47(7):646–9.CrossRefPubMed
52.
Zurück zum Zitat Pucher PH, Lord AC, Sodergren MH, Ahmed AR, Darzi A, Purkayastha S. Reversal to normal anatomy after failed gastric bypass: systematic review of indications, techniques, and outcomes. Surg Obes Relat Dis. 2016;12(7):1351–6.CrossRefPubMed Pucher PH, Lord AC, Sodergren MH, Ahmed AR, Darzi A, Purkayastha S. Reversal to normal anatomy after failed gastric bypass: systematic review of indications, techniques, and outcomes. Surg Obes Relat Dis. 2016;12(7):1351–6.CrossRefPubMed
53.
Zurück zum Zitat Pernar LIM, Kim JJ, Shikora SA. Gastric bypass reversal: a 7-year experience. Surg Obes Relat Dis. 2016;12:1492–8.CrossRefPubMed Pernar LIM, Kim JJ, Shikora SA. Gastric bypass reversal: a 7-year experience. Surg Obes Relat Dis. 2016;12:1492–8.CrossRefPubMed
54.
Zurück zum Zitat Vilallonga R, Van De Vrande S, Himpens J. Laparoscopic reversal of Roux-en-Y gastric bypass into normal anatomy with or without sleeve gastrectomy. Surg Endosc. 2013;27(12):4640–8.CrossRefPubMed Vilallonga R, Van De Vrande S, Himpens J. Laparoscopic reversal of Roux-en-Y gastric bypass into normal anatomy with or without sleeve gastrectomy. Surg Endosc. 2013;27(12):4640–8.CrossRefPubMed
55.
Zurück zum Zitat Carrodeguas L, Szomstein S, Zundel N, Lo Menzo E, Rosenthal R. Gastrojejunal anastomotic strictures following laparoscopic Roux-en-Y gastric bypass surgery: analysis of 1291 patients. Surg Obes Relat Dis. 2006;2(2):92–7.CrossRefPubMed Carrodeguas L, Szomstein S, Zundel N, Lo Menzo E, Rosenthal R. Gastrojejunal anastomotic strictures following laparoscopic Roux-en-Y gastric bypass surgery: analysis of 1291 patients. Surg Obes Relat Dis. 2006;2(2):92–7.CrossRefPubMed
56.
Zurück zum Zitat Ibele AR, Bendewald FP, Mattar SG, McKenna DT. Incidence of gastrojejunostomy stricture in laparoscopic Roux-en-Y gastric bypass using an autologous fibrin sealant. Obes Surg. 2014;24(7):1052–6.CrossRefPubMed Ibele AR, Bendewald FP, Mattar SG, McKenna DT. Incidence of gastrojejunostomy stricture in laparoscopic Roux-en-Y gastric bypass using an autologous fibrin sealant. Obes Surg. 2014;24(7):1052–6.CrossRefPubMed
57.
Zurück zum Zitat Smith MD, Adeniji A, Wahed AS, Patterson E, Chapman W, Courcoulas AP, et al. Technical factors associated with anastomotic leak after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2015;11(2):313–20.CrossRefPubMed Smith MD, Adeniji A, Wahed AS, Patterson E, Chapman W, Courcoulas AP, et al. Technical factors associated with anastomotic leak after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2015;11(2):313–20.CrossRefPubMed
58.
Zurück zum Zitat Jawad A, Bar AH, Merianos D, Zhou J. MALT lymphoma of the gastric remnant after Roux-en-Y gastric bypass. Gastrointest Cancer. 2012;43(Supple(s1)):194–7.CrossRef Jawad A, Bar AH, Merianos D, Zhou J. MALT lymphoma of the gastric remnant after Roux-en-Y gastric bypass. Gastrointest Cancer. 2012;43(Supple(s1)):194–7.CrossRef
59.
Zurück zum Zitat Khitin L, Roses RE, Birkett DH. Cancer in the gastric remnant after gastric bypass: a case report. Curr Surg. 2003;60(5):521–3.CrossRefPubMed Khitin L, Roses RE, Birkett DH. Cancer in the gastric remnant after gastric bypass: a case report. Curr Surg. 2003;60(5):521–3.CrossRefPubMed
61.
Zurück zum Zitat Younan G, Tsai S, Evans DB, Christians KK. A novel reconstruction technique during pancreaticoduodenectomy after Roux-en-Y gastric bypass: how I do it. J Gastrointest Surg. 2017;21(17):1186–91.CrossRefPubMedPubMedCentral Younan G, Tsai S, Evans DB, Christians KK. A novel reconstruction technique during pancreaticoduodenectomy after Roux-en-Y gastric bypass: how I do it. J Gastrointest Surg. 2017;21(17):1186–91.CrossRefPubMedPubMedCentral
Metadaten
Titel
Reconstruction options following pancreaticoduodenectomy after Roux-en-Y gastric bypass: a systematic review
verfasst von
William F. Morano
Mohammad F. Shaikh
Elizabeth M. Gleeson
Alvaro Galvez
Marian Khalili
John Lieb II
Elizabeth P. Renza-Stingone
Wilbur B. Bowne
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
World Journal of Surgical Oncology / Ausgabe 1/2018
Elektronische ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-018-1467-6

Weitere Artikel der Ausgabe 1/2018

World Journal of Surgical Oncology 1/2018 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.